127257 research outputs found
Sort by
Impact of Somatic Loss of CDH1 Locus and/or 16q arm in Breast Cancer Progression
No full textBreast cancer is the most incident and the fifth most mortal cancer worldwide, being the deadliest cancer in females [1]. Current knowledge has highlighted the expression of hormone receptors (estrogen and progesterone) and HER2 as important drivers of clinical intervention and patient care [2].
Additionally, different molecular signatures have been identified in breast cancer with potential prognostic and therapeutic value [3-6], but none has been brought into clinical practice so far.
The 16q loss is one of the most studied chromosomal abnormalities and the second most frequent in breast cancer [7-11], just after 1q gain [12,13]. However, its biological impact and relationship with clinical features have not yet been characterized.
CDH1, encoding the E-cadherin protein, is a well-known tumor suppressor gene located at the 16q chromosome arm, with a proven role in gastric and breast carcinogenesis [14, 15]. While CDH1 complete loss of function (homozygous inactivation) is considered the trigger for the initiation of lobular breast carcinoma [16] and diffuse type gastric cancer [14, 17] partial (heterozygous) or temporary loss of E-cadherin expression is thought to occur during progression of other histological types of gastric and breast cancer [14,18-22].
CDH1 loss of heterozygosity (LOH) has been associated with poor prognosis in intestinal gastric cancer and with lymph node metastasis in sporadic and hereditary diffuse gastric cancer [14, 23]. In breast cancer, loss of 16q chromosome arm occurs in around 30% of the cases [11], and there is an association with good prognosis, since this group is normally characterized by a Luminal A PAM50 subtype [3, 24]. Our purpose is to fine-map deletions in the 16q chromosome arm in a large series of breast cancers from the METABRIC project, and associate the level of CDH1 loss (homozygous or heterozygous) to patients' clinic-pathological features and prognosis (to be performed in Cambridge, Carlos Caldas lab).
With this analysis, we aim to assess the relevance of CDH1 locus loss in breast cancer prognosis and progression.Breast cancer is the most incident and the fifth most mortal cancer worldwide, being the deadliest cancer in females [1]. Current knowledge has highlighted the expression of hormone receptors (estrogen and progesterone) and HER2 as important drivers of clinical intervention and patient care [2].
Additionally, different molecular signatures have been identified in breast cancer with potential prognostic and therapeutic value [3-6], but none has been brought into clinical practice so far.
The 16q loss is one of the most studied chromosomal abnormalities and the second most frequent in breast cancer [7-11], just after 1q gain [12,13]. However, its biological impact and relationship with clinical features have not yet been characterized.
CDH1, encoding the E-cadherin protein, is a well-known tumor suppressor gene located at the 16q chromosome arm, with a proven role in gastric and breast carcinogenesis [14, 15]. While CDH1 complete loss of function (homozygous inactivation) is considered the trigger for the initiation of lobular breast carcinoma [16] and diffuse type gastric cancer [14, 17] partial (heterozygous) or temporary loss of E-cadherin expression is thought to occur during progression of other histological types of gastric and breast cancer [14,18-22].
CDH1 loss of heterozygosity (LOH) has been associated with poor prognosis in intestinal gastric cancer and with lymph node metastasis in sporadic and hereditary diffuse gastric cancer [14, 23]. In breast cancer, loss of 16q chromosome arm occurs in around 30% of the cases [11], and there is an association with good prognosis, since this group is normally characterized by a Luminal A PAM50 subtype [3, 24]. Our purpose is to fine-map deletions in the 16q chromosome arm in a large series of breast cancers from the METABRIC project, and associate the level of CDH1 loss (homozygous or heterozygous) to patients' clinic-pathological features and prognosis (to be performed in Cambridge, Carlos Caldas lab).
With this analysis, we aim to assess the relevance of CDH1 locus loss in breast cancer prognosis and progression
Production of added-value olive polyphenol-lipid based nanoparticles for macrophage modulation
No full text
